作者
Carmelo Tibaldi, Elisa Giovannetti, Enrico Vasile, Valentina Mey, Adrie C Laan, Sara Nannizzi, Roberta Di Marsico, Andrea Antonuzzo, Cinzia Orlandini, Simona Ricciardi, Mario Del Tacca, Godefridus J Peters, Alfredo Falcone, Romano Danesi
发表日期
2008/3/15
期刊
Clinical cancer research
卷号
14
期号
6
页码范围
1797-1803
出版商
American Association for Cancer Research
简介
Purpose: Selecting patients according to key genetic characteristics may help to tailor chemotherapy and optimize the treatment in non–small cell lung cancer (NSCLC). Polymorphisms at the xeroderma pigmentosum group D (XPD), excision repair cross-complementing 1 (ERCC1), and cytidine deaminase (CDA) genes have been associated with alterations in enzymatic activity and may change sensitivity to the widely used cisplatin-gemcitabine regimen.
Experimental Design: Analyses of CDA, XPD, and ERCC1 polymorphisms were done on blood samples of 65 chemotherapy-naïve, advanced NSCLC patients treated with cisplatin-gemcitabine. Furthermore, CDA enzymatic activity was evaluated by high-performance liquid chromatography analysis. Association between XPD Asp312Asn and Lys751Gln, ERCC1 C118T, and CDA Lys27Gln polymorphisms and response, clinical benefit, toxicity, time to …
引用总数
学术搜索中的文章
C Tibaldi, E Giovannetti, E Vasile, V Mey, AC Laan… - Clinical cancer research, 2008